Actively Recruiting
Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO
Led by IRCCS San Raffaele · Updated on 2025-01-27
50
Participants Needed
1
Research Sites
91 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The SURVIVE trial aims to test whether using an anti-thrombotic regimen involving cangrelor can reduce bleeding risk while maintaining effective antithrombotic effects in patients on VA-ECMO due to cardiogenic shock (CS)/ cardiac arrest (CA) who undergo percutaneous coronary intervention (PCI). The investigators plan to achieve this by starting cangrelor on top of systemic anticoagulation with bivalirudin at a low dose, regularly monitoring platelet function, and adjusting the dose based on the results of platelet function assay (Multiplate®) to guarantee effective platelet P2Y12 pathway inhibition to achieve optimal platelet inhibition. Platelet function assays will be performed at various time points throughout the treatment timeframe. Cangrelor will then be stopped at the end of VA-ECMO support, and patients will be transitioned to oral P2Y12- inhibitors as per clinical guidelines.
CONDITIONS
Official Title
Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients aged 18 years
- Patients with acute coronary syndrome-related cardiogenic shock or cardiac arrest undergoing percutaneous coronary intervention with or without stent implantation and requiring VA-ECMO support
- Patients who have received pre-hospital intravenous aspirin loading or are naive to any antithrombotic agent
- Written informed consent provided
You will not qualify if you...
- Uncontrolled bleeding
- Suspected intracranial hemorrhage
- Prior use of any oral P2Y12 inhibitors
- Known history of stroke or transient ischemic attack (TIA)
- Known allergy to cangrelor or its components
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS San Raffaele Hospital
Milan, Italy, Italy, 20132
Actively Recruiting
Research Team
M
Marina Pieri, MD
CONTACT
L
Luca Baldetti, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here